

Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT

Eolia Brissot,¹ Myriam Labopin,^{1,2} Gerhard Ehninger,³ Matthias Stelljes,⁴ Arne Brecht,⁵ Arnold Ganser,⁶ Johanna Tischer,⁷ Nicolaus Kröger,⁸ Boris Afanasyev,⁹ Jürgen Finke,¹⁰ Ahmet Elmaagacli,¹¹ Herman Einsele,¹² Mohamad Mohty^{1,2*} and Arnon Nagler^{2,13*}

¹Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, Paris, France; ²Acute Leukemia Working Party of France, Hôpital Saint Antoine, APHP, Paris, France; ³Universitätsklinikum Dresden, Medizinische Klinik und Poliklinik I, Germany; ⁴University of Münster, Department of Medicine A / Hematology and Oncology, Germany; ⁵Deutsche Klinik für Diagnostik, KMT Zentrum, Wiesbaden, Germany; ⁶Hannover Medical School, Department of Haematology, Hemostasis, Oncology, and Stem Cell Transplantation, Germany; ⁷Klinikum Grosshadern, Med. Klinik III, Munich, Germany; ⁸University Hospital Eppendorf, Bone Marrow Transplantation Centre, Hamburg, Germany; ⁹First State Pavlov Medical University of St. Petersburg, Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology, and Transplantation, Russia; ¹⁰University of Freiburg, Faculty of Medicine and Department of Medicine -Hematology, Oncology and Stem Cell Transplantation, Germany; ¹¹Asklepios Klinik St. Georg, Department of Hematology, Hamburg, Germany; ¹²Universitätsklinikum Würzburg, Med. Klinik und Poliklinik II, Germany and ¹³Hematology Division, Chaim Sheba Medical Center and Tel Aviv University, Tel-Hashomer, Ramat-Gan, Israel

* MM and AN contributed equally to this study and share senior authorship

©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2017.187450

Received: February 4, 2018.

Accepted: October 19, 2018.

Pre-published: October 25, 2018.

Correspondence: EOLIA BRISSOT

eolia.brissot@aphp.fr

Supplementary data

Table S1

Table S1. Univariate analysis for LFS, OS, RI, NRM and GRFS			
	HR	95% CI	P value
<i>LFS</i>			
UD 10/10 vs haplo	0.98	0.80 - 1.22	NS
UD 9/10 vs haplo	1.04	0.83 - 1.32	NS
KPS \geq 90	0.66	0.58 - 0.75	$<10^{-3}$
Poor cytogenetics	1.33	1.11 - 1.59	0.002
Patient CMV positive	1.19	1.04 - 1.37	0.011
centre			$<10^{-3}$
<i>OS</i>			
UD 10/10 vs haplo	0.93	0.74 - 1.16	NS
UD 9/10 vs haplo	1.02	0.8 - 1.3	NS
Time diag to Tx (mo)	0.99	0.99 - 1.00	NS
KPS \geq 90	0.64	0.56 - 0.73	$<10^{-3}$
Poor cytogenetics	1.24	1.03 - 1.49	0.02
Donor female	0.88	0.76 - 1.01	NS
centre			$<10^{-3}$
<i>Relapse</i>			
UD 10/10 vs haplo	0.89	0.70 - 1.14	NS
UD 9/10 vs haplo	0.99	0.76 - 1.30	NS
Time diag to Tx (mo)	0.99	0.98 - 0.99	0.002
age at Tx (per 10y)	0.912	0.865 - 0.962	$<10^{-3}$
Poor cytogenetics	1.40	1.14 - 1.72	0.002
previous auto	0.83	0.55 - 1.25	0. NS
centre (frailty)			$<10^{-3}$
<i>NRM</i>			
UD 10/10 vs haplo	1.1	0.77 - 1.58	NS
UD 9/10 vs haplo	1.03	0.69 - 1.54	NS
age at Tx (per 10y)	1.14	1.06 - 1.23	$<10^{-3}$
Year of Tx	1.04	0.99 - 1.08	NS
KPS \geq 90	0.56	0.45 - 0.68	$<10^{-3}$
previous auto	1.14	0.724 - 1.798	NS
Patient CMV positive	1.30	1.03 - 1.63	0.02
centre			NS

GRFS			
UD 10/10 vs haplo	1.07	0.87 - 1.30	NS
UD 9/10 vs haplo	1.09	0.87 - 1.36	NS
Time diag to Tx (mo)	0.99	0.99 - 1	<10 ⁻³
KPS≥90	0.69	0.62 - 0.79	<10 ⁻³
Poor cytogenetics	1.19	0.99 - 1.41	NS
Donor female	0.84	0.73 - 0.96	0.008
centre			0.005

Abbreviations: CI=confidence interval. Diag=diagnosis. GRFS: graft-versus-host disease-free, relapse-free survival. haplo=haploidentical. HR= hazard ratio. KPS=Karnovsky Performance Status. LFS=leukemia-free survival. MAC=myeloablative conditioning. Mo=month. NRM=non-relapse mortality. OS=overall survival. Rel=relapse. Tx=transplantation. UD=unrelated donor

Table S2

Table S2- Outcomes at 1 year post-HSCT							
1year	Relapse	NRM	LFS	OS	GRFS	chronic GVHD	ext. cGVHD
Haplo PTCy	48.4% [40.9-55.5]	24.4% [18.5-30.8]	27.2% [20.6-33.8]	36.5% [29.3-43.8]	20.5% [14.6-26.5]	17.1% [11.8-23.1]	9.4% [5.6-14.4]
UD 10/10	40% [37-43.1]	24.3% [21.7-26.9]	35.7% [32.7-38.7]	45.1% [42-48.3]	23.5% [20.8-26.2]	22.5% [19.8-25.4]	9.4% [7.5-11.4]
UD 9/10	44.7% [39.5-49.8]	22.8% [18.7-27.3]	32.4% [27.6-37.3]	39.8% [34.6-45]	22.3% [17.9-26.6]	24.8% [20.2-29.7]	9.4% [6.5-12.9]

Abbreviation: ext= extensive. cGVHD= chronic graft-versus-host disease. GRFS= graft-versus-host disease-free, relapse-free survival. haplo= haploidentical. LFS= leukemia-free survival. NRM= non-relapse mortality. OS= overall survival. PTCy= post-transplant cyclophosphamide. RI= relapse incidence. UD=unrelated donors.

List of participating centers, for acknowledgement

University of Muenster, Dept. of Hematol./Oncol., Muenster, Germany; Universitaetsklinikum Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany; Deutsche Klinik fuer Diagnostik, KMT Zentrum, Wiesbaden, Germany; University of Freiburg, Dept. of Medicine -Hematology, Oncology, Freiburg, Germany; Klinikum Grosshadern, Med. Klinik III, Munich, Germany; Hannover Medical School, Department of Haematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover, Germany; Klinikum Nuernberg, 5. Medizinische Klinik, BMT-Unit, Nuernberg, Germany; University Hospital Eppendorf, Bone Marrow Transplantation Centre, Hamburg, Germany; Klinik fuer Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany; Universitaetsklinikum Wuerzburg, Med. Klinik

und Poliklinik II, Wuerzburg, Germany; Chaim Sheba Medical Center, Chaim Sheba Medical Center, Dept. of Bone Marrow Transplantation, Tel-Hashomer, Israel; Universitaet Tuebingen, Medizinische Klinik, Abteilung II, Tuebingen, Germany; CHU Bordeaux, Hôpital Haut-leveque, Pessac, France; Medizinische Universitaet Wien, Klinik fuer Innere Medizin I, Knochenmarktransplantation, Vienna, Austria; Charité - Campus Benjamin Franklin, Universitaetsmedizin Berlin, Medizinische Klinik III - Hämatologie u Onkologie, Berlin, Germany; Asklepios Klinik St. Georg, Department of Haematology, Hamburg, Germany; University Medical Center Schleswig-Holstein, Campus Kiel, División of Stem Cell Transplantation and Immunotherapy, Kiel, Germany; Institute of Hematology and Blood Transfusion, Servicio de Hematología, Prague, Czech Republic; University Regensburg, Dept. of Hematology and Oncology, Regensburg, Germany; Klinikum Augsburg, II Medizinische Klinik, Augsburg, Germany; King Faisal Specialist Hospital & Research Centre, Oncology (Section of Adult Haematology/BMT), Riyadh, Saudi Arabia; University of Heidelberg, Medizinische Klinik u. Poliklinik V, Heidelberg, Germany; University Medical Center Mainz, Department of Hematology, Oncology and Pneumology, Germany, Germany; Charité Universitaetsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik m. S. Hämatologie/Onkologie, A, Berlin, Germany; Hospital Clinic, Institute of Hematology & Oncology, Dept. of Hematology, Barcelona, Spain; Programme de Transplantation&Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France; University Hospital Leipzig, Division of Haematology & Oncology, Leipzig, Germany; Elisabethinen-Hospital, I. Internal Department, Linz, Austria; Philipps Universitaet Marburg, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany; George Papanicolaou General Hospital, Haematology Department / BMT Unit, Thessaloniki, Greece; Nottingham University, Hucknall Road, Nottingham, United Kingdom; St. Bartholomew's and The Royal London NHS Trust, London, United Kingdom; University Hospital Erlangen, Dept. of Internal Medicine 5, Erlangen, Germany; University Hospital Gasthuisberg, Dept. of Hematology, Leuven, Belgium; Rambam Medical Center, Dept. of Hematology & BMT, Haifa, Israel; University Hospital Birmingham NHSTrust, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, United Kingdom; Heinrich Heine Universitaet, Klinik für Hämat,Onkol,Klin.Immun., Duesseldorf, Germany; Azienda Ospedaliera Papa Giovanni XXIII, Hematology and Bone Marrow Transplant Unit, Bergamo, Italy; University Hospital La Fe, Hematology Department, Valencia, Spain; , Nouvel Hopital Civil, Strasbourg, France; Fiona Stanley Hospital, Hematology Department, Perth, Australia; Klinikum Oldenburg, Abt. Onkologie/Hämatologie, Oldenburg, Germany; Tel Aviv Sourasky Medical Center, Blood and Bone Marrow Transplantation, Tel-Aviv, Israel; University Hospital, Hematology, Basel, Switzerland; University Hospital, Clinic of Hematology, Zürich, Switzerland; Hadassah University Hospital, Dept. of Bone Marrow Transplantation, Jerusalem, Israel; BMT unit, Clinica Ematologica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Medical University Graz, LKH - University Hospital Graz, Division of Haematology, Graz, Austria; Beilinson Hospital, Hematology and BMT Department, Petach-Tikva, Israel; Klinikum Rechts der Isar, III Med Klinik der TU, Munich, Germany; University Med. Center, Department of Hematology, Ljubljana, Slovenia; Hôpital Percy, Hematology Department, Clamart, France; Centre Hospitalier Lyon Sud, Pavillon Marcel Bérard -Bat 1G, Service Hematologie, Lyon, France; Southampton General Hospital, Haematology, Oncology, & Paediatrics, Dept. of Haematology, Southampton, United Kingdom; GKT School of Medicine, Dept. of Haematological Medicine, London, United Kingdom; Hopital Saint Antoine, Department of Hematology, Paris, France; Turku University Hospital, TD7 (Stem Cell Transplant Unit), Turku, Finland; Western General Hospital, Dept. of Haematology, Edinburgh, United Kingdom; CHU Nantes, Dept. D`Hematologie, Nantes, France; Hospital Santa Creu i Sant Pau, Hematology Department, Barcelona, Spain; A.Z. Sint-Jan, Dept. of Hematology, Brugge, Belgium; Hospital de Gran Canaria `Dr Negrin`, Servicio de Hematología y Hemoterapia, Las_Palmas, Spain;

Ospedale San Gerardo, Clinica Ematologica dell'Università Milano-Biocca, Monza, Italy; Institut Universitaire du Cancer Toulouse, Oncopole, I.U.C.T-O, Toulouse, France; Ege University Medical School, Dept. of Hematology, Izmir, Turkey; Charles University Hospital, Dept. of Hematology/Oncology, Pilsen, Czech Republic; Central Clinical Hospital, The Medical University of Warsaw, Department of Hematology & Oncol, Warsaw, Poland; Robert_Bosch_Krankenhaus, Abt. Hämatologie / Onkologie, Stuttgart, Germany; Bone Marrow Transplant Unit L 4043, National University Hospital, Rigshospitalet, Copenhagen, Denmark; Cliniques Universitaires St. Luc, Dept. of Haematology, Brussels, Belgium; Bologna University, S.Orsola-Malpighi Hospital, Institute of Hematology & Medical, Oncology L & A Seràgnoli, Bologna, Italy; Hopital Henri Mondor, Sve d` Hematologie, Creteil, France; Hôpitaux Universitaires de Genève, Département des Spécialités de Médecine, Service d'Hématologie, Geneva , Switzerland; Skanes University Hospital, Dept. of Hematology, Lund, Sweden; Sahlgrenska University Hospital, Center for Hematopoietic Cell Transplantation, Hematology Section, Goeteborg, Sweden; CHU Nice - Hôpital de l'ARCHET I, Hematologie Clinique, Nice, France; IRCCS, Casa Sollievo della Sofferenza, Unit of Hematology and Bone Marrow Transplantation, San_Giovanni_Rotondo, Italy; Universitaetsklinikum Goettingen, Abteilung Hämatologie und Onkologie, Goettingen, Germany; University Hospital Maastricht, Dept. Internal Med.Hematology /Oncology, Maastricht, The Netherlands; Az. Ospedaliera S. Croce e Carle, Division of Hematology, Cuneo, Italy; U.O. Ematologia con Trapianto, Azienda Ospedaliero Universitaria Policlinico Bari, Bari, Italy; Umea University Hospital, Hematology, Umeå, Sweden; ICO – Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain; University of Saarland, University Hospital, Dept. of Internal Med., BMT Unit, Homburg, Germany; CHU Lapeyronie, Département d'Hématologie Clinique, Montpellier, France; Hôpital Necker, Service Hematologie Adulte, Paris , France; Centre National de Greffe de Moelle, Tunis, Tunisia; Institut Jules Bordet, Experimental Hematology, Brussels, Belgium; Hopital Jean Minjoz, Service d'Hématologie, Besancon, France; Department of Hematology, Clinic for Cancer, Surgery and Transplantation, Oslo University Hospital, Rikshospitalet, Oslo, Norway; University Hospital, Dept. of Bone Marrow Transplantation, Essen, Germany; Hopital La Miletrie, Head of the Bone Marrow TransplantUnit, Clinical Hematology, Poitiers, France; University Hospital, Dept. of Medicine, Uppsala, Sweden; University Hospital Innsbruck, Internal Medicine V (Hematology & Oncology), Innsbruck, Austria; Inst. Português de Oncologia do Porto, BMT Unit, Porto , Portugal; U.O.S.A Centro Trapianti e Terapia Cellulare, Azienda Ospedaliera Universitaria Senese, Policlinico S.Maria alle Scotte, Portugal, Italy; Univ. Est. de Campinas/TMO/UNICAMP, Cidade Universitaria `Zeferino Vaz`, Campinas, Brazil; Universitaetsklinikum Jena, Klinik für Innere Medizin II, (Abt. Hämatologie und Onkologie), Jena, Germany; Klinik fuer Knochenmarktransplantation, und Hämatologie/Onkologie GmbH, Idar-Oberstein, Germany; Hospital del SAS, Dept. of Hematology, Cádiz, Spain; ICO-Hospital Universitari Germans Trias i Pujol, Cattedra e Servizio di Ematologia, Barcelona, Spain; Ankara University Faculty of Medicine, Dept. of Hematology, Adult Stem Cell Transplantation Unit, Ankara, Turkey; CHRU, Service des Maladies du Sang, Angers, France; Ospedale La Maddalena - Dpt. Oncologico, Unità Operativa di Oncoematologia e, Trapianto di Midollo, Palermo, Italy; Azienda Ospedaliero Universitaria di Udine, Division of Hematology, Udine, Italy; Hospital Clínico, Servicio de Hematología, Salamanca, Spain; Hospital Universitario La Paz, Hematologia-Oncologia, Madrid, Spain; Hospital Morales Meseguer, Unidad de Trasplante de Médula Osea, Serv de Hemat, Murcia, Spain; University Hospital, Dept. of Hematology, Linköping, Sweden; Christie NHS Trust Hospital, Adult Leukaemia and Bone Marrow Transplant Unit, Manchester, United Kingdom; Hospital Gregorio Marañón, Sección de Trasplante de Medula Osea, Madrid, Spain; Antwerp University Hospital (UZA), Dept. of Hematology, Antwerp_Edegem, Belgium; Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Chemnitz,

Germany; Mazzoni Hospital, Haematology Service, Ascoli_Piceno, Italy; Clinical Hematology and BMT Unit, Targu-Mures, Romania; Leiden University Hospital, BMT Centre Leiden, Leiden, The Netherlands; Hopital St. Louis, Dept.of Hematology - BMT, Paris, France; Royal Free Hospital and School of Medicine, Department of Hematology, London, United Kingdom; Bone Marrow Transplant Unit, Beatson, West of Scotland Cancer Centre, Gartnaval General Hospital, Glasgow, United Kingdom; Academisch Ziekenhuis bij de Universiteit, van Amsterdam, Emma Kinderziekenhuis, Amsterdam, The Netherlands; Department of Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; Hope Directorate, St. James`s Hospital, Dublin, Ireland; Universite Paris IV, Hopital la Pitié-Salpêtrière, Hematologie Clinique, Paris, France; Hopital Bretonneau, Service d`Oncologie Médicale, Tours, France; CHU ESTAING, Service d`hématologie clinique Adulte et pédiatrie, Clermont-Ferrand, France; Hôpital HURIEZ, UAM allo-CSH, CHRU, Lille, France; Hospital Clínico Universitario, Servicio de Hematología, Valencia, Spain; Ospedale S. Camillo-Forlanini, Dept. of Hematology and BMT, Rome, Italy; Klinikum Karlsruhe gGmbH, III. Med. Klinik, Haematologie, Onkologie, Karlsruhe, Germany; Goethe-Universitaet, Medizinische Klinik II, Hämatologie, Medizinische Onkologie, Frankfurt am Main, Germany; Department of Haematology, University Hospital of Wales, Cardiff, United Kingdom; Azienda Ospedaliera Universitaria Careggi, Cell Therapy and Transfusion Medicine Unit, Firenze, Italy; Università Cattolica S. Cuore, Istituto di Ematologia, Ematologia, Rome, Italy; Martin-Luther-Universitaet Halle-Wittenberg, Klinik für Innere Medizin IV, Halle, Germany; GATA BMT Center, Gülhane Military Medical Academy, Ankara, Turkey; U.O.D Trapianti di midollo osseo, A.O.R Villa Sofia-Cervello, Palermo, Italy; HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland; Pesaro Hospital, Hematology & Transplant Centre, Pesaro, Italy; University Hospital, Department of Haemato-Oncology, Olomouc, Czech Republic; Azienda Ospedaliera, Centro Unico Regionale Trapianti, Reggio_Calabria, Italy; VU University Medical Center, Department of Hematology (Br 250), Amsterdam, The Netherlands; University Hospital Brno, Dept. of Internal Med. - Hematooncology, Brno, Czech Republic; University Hospital, Department of Hematology and Transfusiology, Bratislava, Slovakia; Erciyes Medical School, Dept. of Hematology - Oncology, Kapadokya (Cappadocia) BMT Center, Kayseri, Turkey; Vilnius University Hospital Santariskiu Klinikos, Haematology, Oncology & Transfusion Center, Vilnius, Lithuania; Hospital Universitari Son Espases, Hematology Service, Palma_De_Mallorca, Spain; Charles University Hospital, 4th Department of Internal Medicine - Hematology, Hradec_Králové, Czech Republic; University of Napoli, `Federico II` Medical School, Division of Hematology, Napoli, Italy; Ospedale A. Businco Cagliari, Haematology & Transplant Centre Wilma Deplano, Cagliari, Italy; Azienda Policlinico Vittorio Emanuele, Programma di Trapianto Emopoietico Misto e Metropolitan Di Catania, Ospedale Ferrarotto, Catania, Italy; Ospedale San Raffaele s.r.l., Haematology and BMT, Milano, Italy; Plymouth Hospitals NHS Trust, Derriford Hospital, Plymouth, United Kingdom; H SS. Antonio e Biagio, Haematology Department, Alessandria, Italy; Medical Park Hospitals, Stem Cell Transplant Unit, Antalya, Turkey; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, China; Sana Klinikum Hameln-Pyrmont, Abt. Haem/Onkologie, Hameln, Germany; USD Trapianti di Midollo, Adulti, Università di Brescia, Brescia, Italy; Adnan Menderes University Med. Faculty, Hematology Department, Aydin, Turkey; Haukeland University Hospital, Department of Haematology, Bergen, Norway; Ospedale San Martino, Department of Haematology II, Genova, Italy; University College London Hospital, Department of Haematology, London, United Kingdom; S.S.C.V.D Trapianto di Cellule Staminali, A.O.U Città della Salute e della Scienza di Torino, Presidio Molinette, Torino, Italy; Hospital de la Princesa, Department of Hematology, Madrid, Spain; University Medical Centre, Dept. of Haematology, Utrecht, The Netherlands; Hospital U. Marqués de Valdecilla, Servicio de Hematología-Hemoterapia, Santander, Spain; Ospedale Civile, Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie, Pescara,

Italy; CHRU St. Etienne, Hopital Nord, Service d'Hematologie Clinique, Saint_Etienne, France; CHU CAEN, Institut d'hématologie de Basse-Normandie, Caen, France; Yorkshire Blood & Marrow Transplant Programme, Haematology Department, Level 3, Bexley Wing, St James's Institute of Oncology, Leeds, United Kingdom; Hopital A. Michallon, Department of Hematology, Grenoble, France; Adult HSCT unit, Northern Centre for Bone Marrow Transplantation, Freeman Hospital, Newcastle-Upon-Tyne, United Kingdom; Birmingham Heartlands Hospital, Department of Haematology, Birmingham, United Kingdom; Hospital San Maurizio, Dept. of Hematology - BMT Unit, Bolzano, Italy; Istituto Clinico Humanitas, Transplantation Unit, Department of Oncology and Haematology, Milano, Italy; Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Bristol Royal Hospital for Children, Dept. of Paediatric Oncology/BMT, Bristol, United Kingdom; Ospedale Dell'Angelo, Hematology Department, Venezia, Italy; University of Cologne, I. Dept. of Medicine, Cologne, Germany; Azienda Ospedaliero Universitaria di Modena Policlinico, Ematologia, Modena, Italy; Dept. Haematology and Stem Cell Transplant, St. István and St. László Hospital, Budapest, Hungary; Hospital Univ. Virgen de las Nieves, Servicio de Hematología, Granada, Spain; Hospital Clinico Universitario, Servicio de Hematología, Santiago_De_Compostela, Spain; Clinic of Hematology, Military Medical Academy, Belgrade, Serbia and Montenegro; National Haematology Centre, Clinic Linezers, Riga, Latvia; Baskent University Hospital, Haematology Division, BMT Unit, Haemaology Reserach Laboratory, Training & Medical, Adana, Turkey; Manchester Royal Infirmary, Clinica Haematology Department, Manchester, United Kingdom; Klinikum Bremen-Mitte, Hämatologie / Onkologie, Klinik für Innere Medizin, Bremen, Germany; Hospital Ramón y Cajal, Servicio de Hematología, Madrid, Spain; Evangelismos Hospital, Division of Hematology, BMT Unit, Athens, Greece; Policlinico G.B. Rossi, Divisione di Ematologia, Unità di TMO, Verona, Italy; Shariati Hospital, Hematology-Oncology and BMT Research, Teheran, Iran; Hospital Universitario Central de Asturias, Oviedo, Spain; C.H.R.U de Brest, Service Onco-Hematologie, Brest, France; Hopital d'Enfants, Hematology, Vandoeuvre_Les_Nancy, France; Silesian Medical Academy, Univ. Dept. of Haematology and BMT, Katowice, Poland; University Hospital SPSK 1, Department of Hematology, Wroclaw, Poland; University of Liege, Dept. of Hematology, CHU Sart-Tilman, Liege, Belgium; Clinica Puerta de Hierro, Servicio de Hematologia y Hemoterapia, Madrid, Spain; Poznan University of Medical Sciences, Department of Hematology, Poznan, Poland; Fundación Favaloro, Buenos_Aires, Argentina; Ghent University Hospital, Haematology, Gent, Belgium; Haematology Department, St.Savvas Oncology Hospital, Athens, Greece; Schneider Children's Medical Center of Israel, BMT Unit, Petach-Tikva, Israel; Ýstanbul Tip Fakultesi, Iç Hastaliklari ABD, Kemik iliði nakil unitesi, CAPA, Istanbul, Turkey; Sezione di Ematologia, Dipartimento di Medicina Clinica e Sperimentale, Università di Perugia, Ospedale Santa Maria della, Perugia, Italy; Military Institute of Health Services BMT Unit, Bone Marrow Transplantation Unit, Warsaw, Poland; Federal Centre of Heart, Blood and Endocrinology, named after V.A. Almazov, Dept. of Hematology, St._Petersburg, Russia; National Research Center for Hematology, Bone Marrow Transplantation, Moscow, Russia; Centre Henri Becquerel, Hematology, Rouen, France; University of Amiens: CHU Amiens, Service d'Hematologie, Amiens, France; St. Franziskus Hospital, Medizinische Klinik I, Flensburg, Germany;